Sustainability & Climate

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

As elder isolation becomes a public health emergency in Quebec, one non-profit's strategy of sustained human connection offers a powerful brand lesson.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Dreame's 2025 holiday sale isn't just about vacuums; it's a strategic play to conquer the UK market with premium tech at aggressive prices.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

CEAT Specialty's new OTR tyre isn't just rubber—it's a strategic play for India's trillion-dollar infrastructure push, blending tech and market savvy.

Taiwan is building a comprehensive cycling ecosystem, blending high-tech hospitality with infrastructure to capture a $135B global tourism market.

An upcoming memoir, "Beyond the Bronx," details one man's journey from incarceration to entrepreneurship, offering a blueprint for personal reinvention.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

Bluerock Acquisition Corp. has raised $150 million. With a sector-agnostic mandate, could this new capital pool target the mining industry?

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

A new pact on quantum computing and AI safety aims to do more than innovate—it seeks to build a secure, equitable digital world for every citizen.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

A 91% strike vote at a NS nursing home reveals deep wage gaps and a staffing crisis, placing the future of elder care at a perilous crossroads.

A new report shows slow progress on fixing ERs and long-term care, raising questions about government accountability and the real-world cost to Ontarians.

On Human Rights Day, Ottawa touts global leadership, but a chasm grows between its international promises and the stagnant progress on justice at home.